Member fees will be applied to members of Forum for Innovative Regenerative Medicine (FIRM) as well as to DIA members. Please send the application form to DIA Japan office by fax or e-mail.
2nd DIA Cell Therapy Products Symposium in Japan
- End to End Development and Implementation: Steady Progress by Industry, Academia, and Government in Practical Use
The development of regenerative medicine in Japan, accelerated by new regulatory and legal systems that began to be scaled into practical use in 2013, has attracted considerable international attention. Currently, research has progressed to the point that many cell therapy products, both inside and outside Japan, are now entering clinical development, and this, in turn, has revealed a number of issues in product development, distribution, and post-marketing.
DIA Japan held its first Cell Therapy Products Symposium last year to bring together stakeholders, particularly from industry and academia, who were involved in developing cell therapy products. The mission was to share insights and exchange ideas with relevant government authorities in order to deepen mutual understanding and resolve issues of concern.
This year, the second Cell Therapy Products Symposium will focus on specific issues and challenges from the beginning of product development to post-marketing of domestic and overseas products, offering a platform for sharing experience and problem-solving efforts by leaders in academia and industry. Overseas trends and combination products with medical devices will be also reviewed. We hope for lively discussions on resolving these issues, and also on charting a direction for future development and business strategies that will be well harmonized internationally.
The DIA Cell Therapy Product Symposium encourages ongoing discussion across industry, academia, and government. We hope that this symposium will continue to grow as a place for sharing knowledge and insights about the latest product developments and as a highly valued networking opportunity for all participants. We look forward to your active participation.
Want to learn more about 2nd DIA Cell Therapy Products Symposium in Japan? You've come to the right site!
Yoji Sato, PhD Head, Division of Drugs
National Institute of Health Sciences, Japan
Yasuko Terao, PhD Head, External Scientific Engagement, R&D Japan Region,
Takeda Pharmaceutical Co., Ltd., Japan
Teruyo Arato, PhD Professor, Clinical Research and Medical Innovation Center
Hokkaido University Hospital, Japan
Masaki Kasai, PhD Reviewer, Office of Cellular and Tissue-based Products,
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Keiji Miyamoto Principal Post-Marketing Regulatory Affairs Dep.
Daiichi Sankyo Co.,Ltd., Japan
Sosuke Miyoshi, PhD
Astellas Pharma Inc., Japan
Hiromi Okabe, PhD Immunology, Regulatory Affairs Japan,Global Drug Development Division
Novartis Pharma K.K, Japan
Hideki Onimatsu, PhD Manager, Regulatory CMC, Regulatory Affairs Department
Takeda Pharmaceutical Company Limited, Japan
Kazuhiro Takekita Instructor, Department of Cardiovascular Surgery, Graduate School of Medicine,
Osaka University, Japan
Kouichi Tsuji General Manager, Clinical Development Department
Terumo Corporation, Japan
Yoshie Tsurumaki Group Manager, Cell & Gene Franchise
Novartis Pharma K.K., Japan
Akiko Ikeda, RPh Associate Director, Regulatory Development Dept.
Janssen Pharmaceutical K.K., Japan
Have an account?